Kymera Therapeutics presented new preclinical data for its oral IRF5 degrader KT‑579 during the Digestive Disease Week (DDW) conference in Chicago, which ran from May 2‑5, 2026. The presentation highlighted disease‑modifying activity in a TNBS inflammatory bowel disease (IBD) model, with results that were comparable to or superior than those of existing biologic and small‑molecule therapies.
The data showed that KT‑579 selectively degraded IRF5 across multiple preclinical species and reduced key inflammatory cytokines—TNFα, IL‑1β and IL‑6—in the TNBS IBD model. Prophylactic dosing prevented body‑weight loss and preserved colon density, indicating robust therapeutic potential in a clinically relevant disease setting.
KT‑579 is an oral IRF5 degrader developed through Kymera’s molecular‑glue platform. The preclinical milestone moves the candidate toward a Phase I healthy‑volunteer trial that is already underway, with Phase I data expected in the second half of 2026. The data position KT‑579 as a potential oral alternative for patients with IBD and other autoimmune disorders.
The presentation underscores Kymera’s progress in translating its platform into tangible therapeutic candidates and may strengthen investor confidence. It also validates the platform’s ability to target disease‑causing proteins, potentially accelerating the company’s broader pipeline.
Presenting the data at DDW—a leading gastroenterology conference—provides a high‑profile venue that reinforces Kymera’s focus on inflammatory diseases and highlights the market opportunity for oral therapies in a field dominated by injectables.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.